Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Lipoprotein(a): the common, likely causal, yet elusive risk factor for cardiovascular disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Weekday variation in triglyceride concentrations in 1.8 million blood samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mobility of HSPG-bound LPL explains how LPL is able to reach GPIHBP1 on capillaries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Monoclonal Antibodies That Bind to the Ly6 Domain of GPIHBP1 Abolish the Binding of LPL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Evolution and Medical Significance of LU Domain-Containing Proteins

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The PCNA interaction motifs revisited: thinking outside the PIP-box

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Angiopoietin-like (ANGPTL) 8 is a secreted inhibitor of lipoprotein lipase (LPL), a key enzyme in plasma triglyceride metabolism. It was previously reported that ANGPTL8 requires another member of the ANGPTL family, ANGPTL3, to act on lipoprotein lipase. ANGPTL3, much like ANGPTL4, is a physiologically relevant regulator of LPL activity, which causes irreversible inactivation of the enzyme. Here we show that ANGPTL8 can form complexes with either ANGPTL3 or ANGPTL4 when the proteins are refolded together from their denatured states. In contrast to the augmented inhibitory effect of the ANGPTL3/ANGPTL8 complex on LPL activity, the ANGPTL4/ANGPTL8 complex is less active compared to ANGPTL4 alone. In our experiments, all three members of the ANGPTL family use the same mechanism to inactivate LPL, which involves dissociation of active dimeric LPL to monomers. This inactivation can be counteracted by the presence of glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1, the endothelial LPL transport protein previously known to protect LPL from spontaneous and ANGPTL4-catalyzed inactivation. Our data demonstrate that ANGPTL8 may function as an important metabolic switch, by forming complexes with ANGPTL3 or with ANGPTL4, in order to direct the flow of energy from triglycerides in blood according to the needs of the body.

OriginalsprogEngelsk
TidsskriftJournal of Lipid Research
ISSN0022-2275
DOI
StatusUdgivet - apr. 2019

ID: 56564932